Actemra (tocilizumab) has been given an emergency use authorization (EUA). This EUA allows for in-hospital use of Actemra as a treatment for COVID-19 in certain cases. You should not take any ...

Actemra (tocilizumab) is a prescription drug that’s used for arthritis and other conditions. The drug is given as an injection under the skin or an intravenous (IV) infusion. Actemra’s dosage depends ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be ...

The FDA said June 24 it has authorized Genentech’s Actemra for treatment of hospitalized COVID-19 patients. Actemra, an intravenous infusion drug with the generic name tocilizumab, is FDA-approved to ...

Tocilizumab-anoh is approved for multiple conditions, including rheumatoid arthritis and COVID-19, in intravenous and subcutaneous formulations. Phase 3 study confirmed biosimilarity between ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra ...

ZURICH, July 19 (Reuters) - Roche's Japanese subsidiary Chugai said on Tuesday subcutaneous injection of its Actemra drug has shown efficacy in rheumatoid arthritis compared to intravenous infusion.

– If approved, Actemra would be the first U.S. FDA-approved immunomodulator for the treatment of COVID-19 in hospitalized patients – – Since the beginning of the pandemic, more than one million people ...

A phase 3 study of tocilizumab (Actemra®) for the treatment of hospitalized patients with severe COVID-19 pneumonia did not meet its primary and key secondary end points. Genentech announced that a ...

Renée Melendez is frustrated with the unvaccinated for more reasons than just the renewed spread of Covid-19, she said. The Virginia woman says she and her whole family got the vaccine as soon as it ...

Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment “Biosimilars continue to be a key growth driver for Organon, and this acquisition complements ...